Structural Determinants of Arrestin Functions - Progress in Molecular Biology and Translational Science - page 86

desensitization of the mu-opioid receptor in Xenopus oocytes. J Biol Chem . 2001;
276:4894 - 4900.
130. Lowe JD, Celver JP, Gurevich VV, Chavkin C. mu-Opioid receptors desensitize less
rapidly than delta-opioid receptors due to less efficient activation of arrestin. J Biol
Chem . 2002;277:15729 - 15735.
131. Sommer ME, Farrens DL, McDowell JH, Weber LA, Smith WC. Dynamics of
arrestin-rhodopsin interactions: loop movement is involved in arrestin activation and
receptor binding. J Biol Chem . 2007;282:25560 - 25568.
132. Hanson SM, Gurevich VV. The differential engagement of arrestin surface charges by
the various functional forms of the receptor. J Biol Chem . 2006;281:3458 - 3462.
133. Coffa S, Breitman M, Hanson SM, et al. The effect of arrestin conformation on the
recruitment of c-Raf1, MEK1, and ERK1/2 activation. PLoS One . 2011;6:e28723.
134. Song X, RamanD, GurevichEV, Vishnivetskiy SA, GurevichVV. Visual and both non-
visual arrestins in their “inactive” conformation bind JNK3 and Mdm2 and relocalize
them from the nucleus to the cytoplasm. J Biol Chem . 2006;281:21491 - 21499.
135. Ahmed MR, Zhan X, Song X, Kook S, Gurevich VV, Gurevich EV. Ubiquitin ligase
parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination.

Biochemistry . 2011;50:3749 - 3763.
136. Breitman M, Kook S, Gimenez LE, et al. Silent scaffolds: inhibition of c-Jun
N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant. J Biol
Chem . 2012;287:19653 - 19664.
137. Smith WC, Gurevich EV, Dugger DR, et al. Cloning and functional characterization
of salamander rod and cone arrestins. Invest Ophthalmol Vis Sci . 2000;41:2445- 2455.
138. Barak LS, Ferguson SS, Zhang J, Caron MG. A beta-arrestin/green fluorescent protein
biosensor for detecting G protein-coupled receptor activation. J Biol Chem .

1997;272:27497 - 27500.
139. Walther C, Nagel S, Gimenez LE, M¨ rl K, Gurevich VV, Beck-Sickinger AG. Ligand-
induced internalization and recycling of the human neuropeptide Y2 receptor is reg-
ulated by its carboxyl-terminal tail. J Biol Chem . 2010;285:41578 - 41590.
140. Gurevich VV, Richardson RM, Kim CM, Hosey MM, Benovic JL. Binding of wild
type and chimeric arrestins to the m2 muscarinic cholinergic receptor. J Biol Chem .
1993;268:16879 - 16882.
141. Gurevich VV, Gurevich EV. Custom-designed proteins as novel therapeutic tools? The
case of arrestins. Expert Rev Mol Med . 2010;12:e13.
142. Gurevich VV, Gurevich EV. Synthetic biology with surgical precision: targeted
reengineering of signaling proteins. Cell Signal . 2012;24:899 - 1908.
143. Gimenez LE, Vishnivetskiy SA, Baameur F, Gurevich VV. Manipulation of very few
receptor discriminator residues greatly enhances receptor specificity of non-visual
arrestins. J Biol Chem . 2012;287:29495 - 29505.
144. Sch¨neberg T, Schulz A, Biebermann H, Hermsdorf T, R¨mpler H, Sangkuhl K.
Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther .
2004;104:173- 206.
145. Goodman Jr OB, Krupnick JG, Santini F, et al. Beta-arrestin acts as a clathrin adaptor in
endocytosis of the beta2-adrenergic receptor. Nature . 1996;383:447 - 450.
146. Wu N, Hanson SM, Francis DJ, et al. Arrestin binding to calmodulin: a direct inter-
action between two ubiquitous signaling proteins. J Mol Biol . 2006;364:955 - 963.
147. Laporte SA, Oakley RH, Zhang J, et al. The beta2-adrenergic receptor/betaarrestin
complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci
USA . 1999;96:3712 - 3717.
148. McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptor-regulated
MAPK scaffold for the activation of JNK3. Science . 2000;290:1574- 1577.